“Non-Small Cell Lung Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Small Cell Lung Cancer Market.
The Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Non-Small Cell Lung Cancer Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Non-Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.
-
Non-Small Cell Lung Cancer companies working in the treatment market are Merck Sharp & Dohme LLC, Qilu Pharmaceutical Co., Ltd., Merus N.V., Zymeworks BC Inc., AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others, are developing therapies for the Non-Small Cell Lung Cancer treatment
-
Emerging Non-Small Cell Lung Cancer therapies in the different phases of clinical trials are- V940, QL1706, Zenocutuzumab (MCLA-128), ZW49, Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7;Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Trastuzumab deruxtecan, DS-1062a, Durvalumab, Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Domvanalimab, ONO-4538, M7824, Retifanlimab, Lenvatinib, and others are expected to have a significant impact on the Non-Small Cell Lung Cancer market in the coming years.
-
In January 2024, Gilead Sciences announced that the Phase 3 EVOKE-01 study failed to achieve its primary endpoint of overall survival (OS) in patients with previously treated metastatic non-small cell lung cancer (NSCLC). The study compared Trodelvy (sacituzumab govitecan-hziy; SG) with docetaxel in patients with metastatic or advanced NSCLC who had progressed after platinum-based chemotherapy and checkpoint inhibitor therapy.
-
In February 2024, The FDA has granted breakthrough therapy designation to BAY 2927088, a new oral small molecule tyrosine kinase inhibitor (TKI), for the treatment of patients with unresectable or metastatic HER2-mutated non-small cell lung cancer (NSCLC).
-
In June 2023, BioNTech SE announced that the first patient with non-small cell lung cancer (NSCLC) has been treated in a pivotal Phase 3 trial assessing their next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart). This trial is a key component of BioNTech’s plan to launch several pivotal trials in 2023 and 2024.
Non-Small Cell Lung Cancer Overview
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. It typically grows and spreads more slowly than small cell lung cancer (SCLC). NSCLC includes several subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each originating from different types of lung cells. Risk factors include smoking, exposure to carcinogens, and genetic predispositions. Symptoms may include persistent cough, chest pain, and shortness of breath. NSCLC is often diagnosed through imaging and biopsy, with treatments ranging from surgery and radiation to targeted therapies and immunotherapy.
Get a Free Sample PDF Report to know more about Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight
Emerging Non-Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:
-
V940: Merck Sharp & Dohme LLC
-
QL1706: Qilu Pharmaceutical Co., Ltd.
-
Zenocutuzumab (MCLA-128): Merus N.V.
-
ZW49: Zymeworks BC Inc.
-
Ensartinib (X-396): Xcovery
-
SAR408701: Sanofi
-
Hyleukin-7 (NT-I7;Efineptakin Alfa): NeoImmune Tech
-
Avelumab (Bavencio): Merck KGaA and Pfizer
-
Sitravatinib: Mirati Therapeutics
-
Trastuzumab deruxtecan: AstraZeneca
-
DS-1062a: Daiichi Sankyo, Inc.
-
Durvalumab: Parexel
-
Sacituzumab Govitecan-hziy (SG): Gilead Sciences
-
Pembrolizumab: Merck Sharp & Dohme LLC
-
Domvanalimab: Arcus Biosciences, Inc.
-
ONO-4538: Ono Pharmaceutical Co. Ltd
-
M7824: EMD Serono
-
Retifanlimab: Incyte Corporation
-
Lenvatinib: Eisai Inc.
Non-Small Cell Lung Cancer Route of Administration
Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Non-Small Cell Lung Cancer Molecule Type
Non-Small Cell Lung Cancer Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
-
Non-Small Cell Lung Cancer Assessment by Product Type
-
Non-Small Cell Lung Cancer By Stage and Product Type
-
Non-Small Cell Lung Cancer Assessment by Route of Administration
-
Non-Small Cell Lung Cancer By Stage and Route of Administration
-
Non-Small Cell Lung Cancer Assessment by Molecule Type
-
Non-Small Cell Lung Cancer by Stage and Molecule Type
DelveInsight’s Non-Small Cell Lung Cancer Report covers around 120+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Non-Small Cell Lung Cancer product details are provided in the report. Download the Non-Small Cell Lung Cancer pipeline report to learn more about the emerging Non-Small Cell Lung Cancer therapies
Some of the key companies in the Non-Small Cell Lung Cancer Therapeutics Market include:
Key companies developing therapies for Non-Small Cell Lung Cancer are – Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, Sanofi, Astellas Pharma Inc., and others.
Non-Small Cell Lung Cancer Pipeline Analysis:
The Non-Small Cell Lung Cancer pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Small Cell Lung Cancer Treatment.
-
Non-Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Small Cell Lung Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Non-Small Cell Lung Cancer drugs and therapies
Non-Small Cell Lung Cancer Pipeline Market Drivers
-
Premium-price targeted agents with better clinical profile and expansion of therapies in the first-line expected to drive the growth of NSCLC market, the development of therapies targeting specific mutations are expected to dominate the upcoming market, are some of the important factors that are fueling the Non-Small Cell Lung Cancer Market.
Non-Small Cell Lung Cancer Pipeline Market Barriers
-
However, Potential for premium pricing of emerging therapies by showing an edge over current therapies Uptake of potential emerging therapies with better clinical profile, specificity towards mutations occurs in NSCLC and therapies to overcome resistance expected to be fast, and other factors are creating obstacles in the Non-Small Cell Lung Cancer Market growth.
Scope of Non-Small Cell Lung Cancer Pipeline Drug Insight
-
Coverage: Global
-
Key Non-Small Cell Lung Cancer Companies: Merck Sharp & Dohme LLC, Qilu Pharmaceutical Co., Ltd., Merus N.V., Zymeworks BC Inc., AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others
-
Key Non-Small Cell Lung Cancer Therapies: V940, QL1706, Zenocutuzumab (MCLA-128), ZW49, Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7;Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Trastuzumab deruxtecan, DS-1062a, Durvalumab, Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Domvanalimab, ONO-4538, M7824, Retifanlimab, Lenvatinib, and others
-
Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies
-
Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers
Request for Sample PDF Report for Non-Small Cell Lung Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Non-Small Cell Lung Cancer Report Introduction
2. Non-Small Cell Lung Cancer Executive Summary
3. Non-Small Cell Lung Cancer Overview
4. Non-Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment
5. Non-Small Cell Lung Cancer Pipeline Therapeutics
6. Non-Small Cell Lung Cancer Late Stage Products (Phase II/III)
7. Non-Small Cell Lung Cancer Mid Stage Products (Phase II)
8. Non-Small Cell Lung Cancer Early Stage Products (Phase I)
9. Non-Small Cell Lung Cancer Preclinical Stage Products
10. Non-Small Cell Lung Cancer Therapeutics Assessment
11. Non-Small Cell Lung Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non-Small Cell Lung Cancer Key Companies
14. Non-Small Cell Lung Cancer Key Products
15. Non-Small Cell Lung Cancer Unmet Needs
16 . Non-Small Cell Lung Cancer Market Drivers and Barriers
17. Non-Small Cell Lung Cancer Future Perspectives and Conclusion
18. Non-Small Cell Lung Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Non-Small Cell Lung Cancer Pipeline Dynamics 2024: FDA Approvals, Therapies, MOA, ROA, and Developments | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Merck Sharp